Oxycodone (OXY) antibody and antigen (hapten, BSA/OVA conjugated)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-SMT-240-Ag01	BSA-Oxycodone (OXY)	756
GMP-SMT-240-Ag02	OVA-Oxycodone (OXY)	756
GMP-SMT-240-Ab01	Anti-human Oxycodone (OXY) mouse monoclonal antibody (mAb)	1953
GMP-SMT-240-Ab02	Anti-human Oxycodone (OXY) human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-SMT-240-Ag01
Product Name	BSA-Oxycodone (OXY)
Target/Biomarker	Oxycodone (OXY)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Oxycodone (OXY) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in OXY level test of Pain () and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Oxycodone (OXY) / OVA-Oxycodone (OXY) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-240-Ag02
Product Name	OVA-Oxycodone (OXY)
Target/Biomarker	Oxycodone (OXY)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Oxycodone (OXY) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in OXY level test of Pain () and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Oxycodone (OXY) / OVA-Oxycodone (OXY) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-240-Ab01
Product Name	Anti-human Oxycodone (OXY) mouse monoclonal antibody (mAb)
Target/Biomarker	Oxycodone (OXY)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Oxycodone (OXY) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in OXY level test of Pain () and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Oxycodone (OXY) / OVA-Oxycodone (OXY) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-240-Ab02
Product Name	Anti-human Oxycodone (OXY) human monoclonal antibody (mAb)
Target/Biomarker	Oxycodone (OXY)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Oxycodone (OXY) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in OXY level test of Pain () and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Oxycodone (OXY) / OVA-Oxycodone (OXY) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

1. Oxycodone: An In-Depth Examination of its Role in In Vitro Diagnosis (IVD) Oxycodone, a potent opioid analgesic, holds a critical position in the realm of pain management. This pharmaceutical compound is widely utilized for the effective alleviation of moderate to severe pain by virtue of its interaction with opioid receptors in the central nervous system. In the context of in vitro diagnosis (IVD), Oxycodone emerges as a pivotal molecule serving as a primary target for diagnostic assays. Our esteemed biopharmaceutical company specializes in offering an extensive range of resources tailored to the precise measurement and detection of Oxycodone levels. This includes anti-Oxycodone antibodies and an expansive suite of small molecule competitive antigens. Within this specialized portfolio, we offer Carrier-coupled antigens, immunogens, hapten-carrier conjugates, BSA-conjugated, and OVA-conjugated forms. These meticulously engineered reagents are purposefully designed to facilitate the development of advanced diagnostic assays, enabling the accurate quantification and detection of Oxycodone within diverse biological samples, encompassing blood and urine. 2. The Significance of Oxycodone Measurement in In Vitro Diagnosis (IVD) The measurement of Oxycodone stands as an imperative within the landscape of in vitro diagnosis (IVD) for an array of compelling reasons, each possessing distinct clinical and scientific implications: a. Optimized Therapeutic Oversight: Patients undergoing Oxycodone therapy necessitate vigilant monitoring to ensure precise dosing that effectively manages pain while mitigating the potential for adverse effects or overdose. Accurate Oxycodone measurement empowers healthcare professionals to tailor treatment regimens to the unique and evolving needs of individual patients, thereby enhancing the quality of care provided. b. Mitigation of Misuse and Dependence: Oxycodone's classification as a controlled substance underscores its propensity for misuse and the development of physical dependence. Routine measurement of Oxycodone levels serves as a critical tool for healthcare providers in assessing patient adherence and promptly identifying any signs of medication misuse. This early detection facilitates timely intervention and the provision of appropriate support. c. Enhanced Pain Management Strategies: The accuracy of Oxycodone measurement is integral to the optimization of pain management strategies. This ensures that patients receive the precise dosage required to effectively alleviate pain, ultimately enhancing their overall quality of life and minimizing unnecessary suffering. d. Pharmaceutical Research and Development: Within the sphere of pharmaceutical research and development, a comprehensive understanding of Oxycodone's pharmacokinetics and metabolic pathways is of paramount importance. In vitro diagnostic (IVD) assays customized for Oxycodone offer invaluable insights for drug discovery, safety evaluations, and the creation of innovative therapies specifically targeting pain management. In summary, the precise measurement of Oxycodone stands as a cornerstone within the expansive field of in vitro diagnosis (IVD). It contributes significantly to therapeutic oversight, the prevention of misuse, the enhancement of pain management, and progress in pharmaceutical research. Our specialized product portfolio, meticulously crafted for Oxycodone testing, plays an indispensable role in enabling accurate and sensitive quantification. This, in turn, not only advances patient care but also fosters scientific exploration in the realm of pain management strategies and opioid pharmacology. As the field of IVD continues to evolve, our unwavering commitment to providing innovative solutions for Oxycodone measurement remains steadfast, further enhancing our understanding of this vital therapeutic agent's multifaceted role.

About GDU